As filed with the Securities and Exchange Commission on February 25, 2021

Registration No. 333-

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

Apellis Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Delaware   27-1537290

(State or Other Jurisdiction of

Incorporation or Organization)

 

(I.R.S. Employer

Identification No.)

100 Fifth Avenue

Waltham, MA

  02451
(Address of Principal Executive Offices)   (Zip Code)

2017 Stock Incentive Plan

2020 Inducement Stock Incentive Plan

(Full Title of the Plan)

Cedric Francois, M.D., Ph.D.

President and Chief Executive Officer

Apellis Pharmaceuticals, Inc.

100 Fifth Avenue

Waltham, MA 02451

(Name and Address of Agent for Service)

(617) 977-5700

(Telephone Number, Including Area Code, of Agent for Service)

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

 

 

CALCULATION OF REGISTRATION FEE

 

 

Title of Securities
to be Registered
  Amount to be
Registered(1)
 

Proposed

Maximum

Offering Price

Per Share

 

Proposed

Maximum

Aggregate

Offering Price

 

Amount of

Registration Fee

Common Stock, $0.0001 par value per share

  3,345,189 shares(2)   $45.04(3)   $150,667,313(3)   $16,438

 

 

(1)

In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.

(2)

Represents (1) 3,045,189 additional shares of Common Stock authorized for issuance under the 2017 Stock Incentive Plan (the “2017 Plan”) and (2) 300,000 additional shares of Common Stock authorized for issuance under the 2020 Inducement Stock Incentive Plan (the “2020 Plan”).

(3)

Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act of 1933, as amended. The price per share and aggregate offering price are based on the average of the high and low prices of the registrant’s Common Stock as reported on the Nasdaq Global Select Market on February 23, 2021.

 

 

 


EXPLANATORY NOTE

This Registration Statement on Form S-8 is being filed by Apellis Pharmaceuticals, Inc., a Delaware corporation (the “registrant”), to register (a) 3,045,189 additional shares of the registrant’s common stock, $0.0001 par value per share (“Common Stock”), issuable under the registrant’s 2017 Stock Incentive Plan (the “2017 Plan”) and (b) 300,000 shares of Common Stock issuable under the 2020 Inducement Stock Incentive Plan (the “2020 Plan”. Pursuant to General Instruction E to Form S-8, this registration statement incorporates by reference the contents of (i)  the registration statement on Form S-8, File No. 333-221528, filed by the registrant on November 13, 2017 relating to the 2017 Plan, (ii)  the registration statement on Form S-8, File No. 333-229876, filed by the registrant on February 26, 2019 relating to the 2017 Plan, (iii)  the registration statement on Form S-8, File No. 333-236708, filed by the registrant on February 27, 2020 relating to the 2017 Plan and (iv)  the registration statement on Form S-8, File No. 333-236710, filed by the registrant on February 27, 2020 relating to the 2020 Plan, except (x) to the extent superseded hereby and (y) for Item 8, Exhibits, with respect to which the Exhibit Index immediately preceding the exhibits attached hereto is incorporated herein by reference.


Item 8. Exhibits.

 

Exhibit
Number

  

Description of Exhibit

4.1    Restated Certificate of Incorporation of the registrant (filed as Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed on November 13, 2017 and incorporated herein by reference)
4.2    Amended and Restated By-Laws of the registrant (filed as Exhibit 3.2 to the registrant’s Current Report on Form 8-K filed on November 13, 2017 and incorporated herein by reference)
5.1    Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the registrant
23.1    Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1)
23.2    Consent of Ernst & Young LLP, independent registered public accounting firm
23.3    Consent of Deloitte & Touche LLP, independent registered public accounting firm
24.1    Power of Attorney (included on the signature page)
99.1    2017 Stock Incentive Plan (filed as Exhibit 10.4 to the registrant’s Amendment No.  3 to the registrant’s Registration Statement on Form S-1 filed on October 30, 2017 (File No.  333-220941) and incorporated herein by reference)
99.2    2020 Inducement Stock Incentive Plan (filed as Exhibit 99.1 to the registrant’s Registration Statement on S-8 filed on February 27, 2020 (File No. 333-236710) and incorporated herein by reference)


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Waltham, Commonwealth of Massachusetts on this 25th day of February, 2021.

 

APELLIS PHARMACEUTICALS, INC.

By:   /s/ Cedric Francois
 

Cedric Francois, M.D., Ph.D.

 

President and Chief Executive Officer


POWER OF ATTORNEY AND SIGNATURES

We, the undersigned officers and directors of Apellis Pharmaceuticals, Inc., hereby severally constitute and appoint Cedric Francois, Timothy Sullivan and David O. Watson and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Apellis Pharmaceuticals, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature

  

Title

  

Date

/s/ Cedric Francois

  

President, Chief Executive Officer and Director

(principal executive officer)

   February 25, 2021
Cedric Francois, M.D., Ph.D.

/s/ Timothy Sullivan

  

Chief Financial Officer and Treasurer

(principal financial officer)

   February 25, 2021
Timothy Sullivan

/s/ Nicole Perry

Nicole Perry

  

Vice President of Finance

(principal accounting officer)

   February 25, 2021

/s/ Gerald Chan, D.Sc.

Gerald Chan, D.Sc.

   Chairman of the Board of Directors    February 25, 2021

/s/ A. Sinclair Dunlop

A. Sinclair Dunlop

   Director    February 25, 2021

/s/ Paul Fonteyne

Paul Fonteyne

   Director    February 25, 2021

/s/ Alec Machiels

Alec Machiels

   Director    February 25, 2021

/s/ Stephanie Monaghan O’Brien

Stephanie Monaghan O’Brien

   Director    February 25, 2021